Daiichi Sankyo has expanded its presence in Canada with the official opening of its permanent headquarters in Toronto, including additional operational and R&D investments to advance its efforts in oncology.

“Establishing a permanent headquarters in Toronto represents a significant milestone in our global expansion and reflects the strong commitment of Daiichi Sankyo to patients and partners in Canada,” said Masahiro Kato, Managing Director, Europe and Canada, Daiichi Sankyo. “Canada is home to a vibrant healthcare and life sciences ecosystem where we see immense potential for continued growth through scientific innovation and collaboration, solidifying Canada’s role as a global contributor to improve standards of care.”

Over the past two years, Daiichi Sankyo has supported 18 oncology clinical trials across 43 sites in Canada, working with cancer centers such as Princess Margaret Cancer Centre, CHUM, BC Cancer, McGill University Health Centre and The Ottawa Hospital.